scholarly journals The Effects of Ezetimibe on Surrogate Markers of Cholesterol Absorption and Synthesis in Japanese Patients with Dyslipidemia

2010 ◽  
Vol 17 (1) ◽  
pp. 106-114 ◽  
Author(s):  
Shinya Hiramitsu ◽  
Yoshiaki Ishiguro ◽  
Hiroyuki Matsuyama ◽  
Kenji Yamada ◽  
Kazuo Kato ◽  
...  
Keyword(s):  
Japanese Patients ◽  
Cholesterol Absorption ◽  
Surrogate Markers

scholarly journals Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome

2011 ◽  
Vol 107 (5) ◽  
pp. 705-711 ◽  
Author(s):  
Caroline Richard ◽  
Patrick Couture ◽  
Sophie Desroches ◽  
Suzanne Benjannet ◽  
Nabil G. Seidah ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Weight Loss ◽  
Body Weight ◽  
Control Diet ◽  
Cholesterol Absorption ◽  
Energy Restriction ◽  
Surrogate Markers ◽  
The Metabolic Syndrome ◽  
The Mediterranean ◽  
The Impact

The mechanisms implicated in the LDL-cholesterol (LDL-C)-lowering effects of the Mediterranean-type diet (MedDiet) are unknown. The present study assessed the impact of the MedDiet consumed under controlled feeding conditions, with and without weight loss, on surrogate markers of cholesterol absorption, synthesis and clearance using plasma phytosterols, lathosterol and proprotein convertase subtilisin/kexin-9 (PCSK9) concentrations, respectively, in men with the metabolic syndrome. The subjects' diet (n19, 24–62 years) was first standardised to a baseline North American control diet (5 weeks) followed by a MedDiet (5 weeks), both under weight-maintaining isoenergetic feeding conditions. The participants then underwent a 20-week free-living energy restriction period (10 (sd3) % reduction in body weight,P < 0·01), followed by the consumption of the MedDiet (5 weeks) under controlled isoenergetic feeding conditions. The LDL-C-lowering effect of the MedDiet in the absence of weight loss ( − 9·9 %) was accompanied by significant reductions in plasma PCSK9 concentrations ( − 11·7 %,P < 0·01) and in the phytosterol:cholesterol ratio ( − 9·7 %,P < 0·01) compared with the control diet. The addition of weight loss to the MedDiet had no further impact on plasma LDL-C concentrations and on these surrogate markers of LDL clearance and cholesterol absorption. The present results suggest that the MedDiet reduces plasma LDL-C concentrations primarily by increasing LDL clearance and reducing cholesterol absorption, with no synergistic effect of body weight loss in this process.

scholarly journals Influence of Chitosan Treatment on Surrogate Serum Markers of Cholesterol Metabolism in Obese Subjects

2018 ◽  
Author(s):  
Dieter Lütjohann ◽  
Milka Marinova ◽  
Karsten Wolter ◽  
Winfried Willinek ◽  
Norman Bitterlich ◽  
...  
Keyword(s):  
Bile Acid ◽  
Ldl Cholesterol ◽  
Cholesterol Metabolism ◽  
Cholesterol Absorption ◽  
Acid Synthesis ◽  
Placebo Treatment ◽  
Bile Acid Synthesis ◽  
Cholesterol Concentration ◽  
Surrogate Markers ◽  
Obese Subjects

Chitosan treatment results in significantly lower serum LDL cholesterol concentrations. To assess the working mechanism of chitosan, we measured serum surrogate markers of cholesterol absorption (campesterol, sitosterol, cholestanol), synthesis (lathosterol, lanosterol, desmosterol), and degradation to bile acids (7&alpha;-hydroxy-cholesterol, 27-hydroxy-cholesterol) corrected for cholesterol concentration (R_sterols). Over 12 weeks, 116 obese subjects (BMI 31.7, range 28.1 &ndash; 38.9 kg/m2) were studied under chitosan (n=61) and placebo treatment (n=55). The participants were briefly educated regarding improvement of nutrition quality and energy expenditure. Daily chitosan intake was 3200 mg. Serum LDL cholesterol concentration decreased significantly more (P=0.0252) under chitosan (-8.67 &plusmn; 18.18 mg/dl, 5.6%) than under placebo treatment (-1.00 &plusmn; 24.22 mg/dl, 0.9%). This reduction was not associated with the expected greater decreases in markers of cholesterol absorption under chitosan treatment. Also, increase in markers of cholesterol synthesis and bile acid synthesis under chitosan treatment was not any greater than under placebo treatment. In conclusion, a significant selective reduction of serum LDL cholesterol under chitosan treatment is neither associated with a reduction of serum surrogate markers of cholesterol absorption nor with an increases of markers for cholesterol and bile acid synthesis.

scholarly journals Influence of Chitosan Treatment in Obese Subjects on Surrogate Plasma Markers of Cholesterol Metabolism

2018 ◽  
Author(s):  
Dieter Lütjohann ◽  
Milka Marinova ◽  
Karsten Wolter ◽  
Winfried Willinek ◽  
Norman Bitterlich ◽  
...  
Keyword(s):  
Bile Acid ◽  
Ldl Cholesterol ◽  
Cholesterol Metabolism ◽  
Cholesterol Absorption ◽  
Acid Synthesis ◽  
Placebo Treatment ◽  
Bile Acid Synthesis ◽  
Cholesterol Concentration ◽  
Surrogate Markers ◽  
Obese Subjects

Chitosan treatment results in significantly lower plasma LDL-cholesterol concentrations. To test the working mechanism of Chitosan, we measured plasma surrogate markers of cholesterol absorption, synthesis, and degradation to bile acids corrected for cholesterol concentration (R_sterols). One hundred sixteen obese subjects (BMI 31.7, range 28.1 &ndash; 38.9 kg/m2) were studied under Chitosan treatment (n=61) and placebo treatment (n=55) during 12 weeks. The participants underwent a short nutrition education on how to improve quality of nutrition and energy expenditure. Daily Chitosan intake was 3200 mg. RESULTS. Plasma LDL-cholesterol concentration decreased significantly stronger (P=0.0252) under Chitosan (-8.67 &plusmn; 18.18 mg/dl, 5.6%) than under placebo treatment (-1.00 &plusmn; 24.22 mg/dl, 0.9%). This reduction was not associated with corresponding decreases of markers of cholesterol absorption under Chitosan treatment. As a marker for cholesterol synthesis R_lathosterol showed a trend towards a stronger decrease under Chitosan treatment (P=0.0759). Regarding markers of bile acid synthesis, R_7&alpha;-hydroxy-cholesterol decreased significantly only under Chitosan treatment, but not stronger than under placebo treatment. In conclusion, a significant selective reduction of plasma LDL-cholesterol under Chitosan treatment is neither associated with an expected reduction of plasma surrogate markers of cholesterol absorption nor with expected increases of markers for cholesterol and bile acid synthesis.

Sign in / Sign up

Export Citation Format

Share Document